{"id":"extended-course-macrolide","safety":{"commonSideEffects":[{"rate":"10-30","effect":"Gastrointestinal disturbance (nausea, diarrhea, abdominal discomfort)"},{"rate":"1-5","effect":"Hearing loss or ototoxicity"},{"rate":"1-3","effect":"QT prolongation"},{"rate":"5-15","effect":"Headache"},{"rate":"5-10","effect":"Taste disturbance"}]},"_chembl":{"chemblId":"CHEMBL2108492","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Macrolides, particularly azithromycin, possess anti-inflammatory properties beyond their antimicrobial action, including inhibition of mucus hypersecretion, reduction of pro-inflammatory cytokine production, and modulation of neutrophil and macrophage function. When administered as extended courses at sub-antimicrobial doses, these agents can suppress chronic airway inflammation and improve clinical outcomes in conditions characterized by persistent inflammation.","oneSentence":"Extended course macrolide antibiotics reduce airway inflammation and modulate immune responses in chronic respiratory conditions through anti-inflammatory and immunomodulatory effects.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:11:59.902Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic airway inflammatory diseases (likely cystic fibrosis, bronchiectasis, or diffuse panbronchiolitis)"},{"name":"Chronic obstructive pulmonary disease with inflammatory phenotype"}]},"trialDetails":[{"nctId":"NCT04185402","phase":"PHASE4","title":"Azithromycin Reduction to Reach Elimination of Trachoma","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2021-05-29","conditions":"Trachoma","enrollment":3931},{"nctId":"NCT06289647","phase":"PHASE4","title":"Azithromycin Reduction to Reach Elimination of Trachoma B","status":"WITHDRAWN","sponsor":"University of California, San Francisco","startDate":"2024-10","conditions":"Trachoma","enrollment":""},{"nctId":"NCT02735707","phase":"PHASE3","title":"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia","status":"RECRUITING","sponsor":"UMC Utrecht","startDate":"2016-04-11","conditions":"Community-acquired Pneumonia, Influenza, COVID-19","enrollment":20000},{"nctId":"NCT00645086","phase":"PHASE3","title":"Comparative Study of 5 Days of M02-472 Clarithromycin Extended-Release Tablets to 7 Days of Clarithromycin Immediate-Release Tablets for the Treatment of Exacerbation of Chronic Bronchitis","status":"COMPLETED","sponsor":"Abbott","startDate":"2002-12","conditions":"Acute Bacterial Exacerbation of Chronic Bronchitis (ABECB).","enrollment":465}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":23,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Extended course macrolide","genericName":"Extended course macrolide","companyName":"UMC Utrecht","companyId":"umc-utrecht","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Extended course macrolide antibiotics reduce airway inflammation and modulate immune responses in chronic respiratory conditions through anti-inflammatory and immunomodulatory effects. Used for Chronic airway inflammatory diseases (likely cystic fibrosis, bronchiectasis, or diffuse panbronchiolitis), Chronic obstructive pulmonary disease with inflammatory phenotype.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}